Abstract 919P
Background
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET-CT) is a non-invasive imaging modality. This study aimed to investigate the effects of radiometric parameters and clinical characteristics of 18F-FDG PET-CT on the prognosis of patients with nasopharyngeal carcinoma (NPC).
Methods
A total of 801 patients with metastatic NPC were enrolled between 2016 and 2020, and all participants underwent 18F-FDG PET/CT before treatment. We assessed the following 18F-FDG PET parameters: standardized uptake value (SUV), SUV-avg (average), SUV-peak (maximum), and total lesion glycolysis (TLG) of the primary tumor and regional lymph nodes. We used multivariate Cox proportional hazards models and multiple machine learning techniques to identify independent predictors of survival based on radiomic parameters and patient clinical characteristics. After selecting the features, we established prognosis models using a COX stepwise regression model. Finally, we performed internal validation, and a nomogram was created for NPC comprehensive diagnosis.
Results
In this study, we developed a stable and robust model incorporating five independent prognostic features based on COX regression. The area under the curve (AUC) of the model was 0.75 (95% CI = 0.52–0.97) at 1 year, 0.80 (95% CI = 0.71–0.89) at 3 years, and 0.86 (95% CI = 0.78–0.94) at 5 years. The AUC at 3 years and 5 years were calculated as 0.7276 and 0.7242, respectively. The model was validated using receiver operating characteristic (ROC), consistency index, and multivariate analysis, which showed high accuracy and consistent performance. Moreover, patients in the low-risk score group exhibited significantly better outcomes than those in the high-risk score group (P < 0.001).
Conclusions
Our findings suggest that age, SUV-Tmax, SUV-Tavg, SUV-Tpeak, and TLG-T are valuable parameters for predicting long-term survival in patients with NPC. The nomogram based on metabolic parameters combined with other variables showed good prognostic accuracy in predicting NPC prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
818TiP - REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)
Presenter: R. Wendel Naumann
Session: Poster session 12
819TiP - FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours
Presenter: Funda Meric-Bernstam
Session: Poster session 12
820TiP - A randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG 3067/SOCCER-P trial)
Presenter: Hyun-woong Cho
Session: Poster session 12
821TiP - Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
Presenter: Geoffrey Shapiro
Session: Poster session 12
862P - Clinical utility of circulating tumor HPV16 DNA detection in plasma from oropharyngeal squamous cell carcinoma patients
Presenter: Ana Carolina de Carvalho
Session: Poster session 12
863P - Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
Presenter: Danilo Galizia
Session: Poster session 12
864P - Serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery
Presenter: Grégoire Marret
Session: Poster session 12
865P - Molecular analysis of surgical margins in early oral carcinomas (OSCC)
Presenter: Antoine Moya-Plana
Session: Poster session 12
866P - Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer
Presenter: Geoffrey Liu
Session: Poster session 12
867P - Predicting HPV-association using regular H&E slides can identify subgroups of patients with favorable prognosis at a highly detailed level
Presenter: Jens Peter Klussmann
Session: Poster session 12